Slynd birth control drugmaker Exeltis hit with FDA letter over misleading social media promotion
2023-08-21
A sponsored social media post for Slynd birth control is the latest ad offender in the eyes of the FDA’s promotions watchdog. The Office of Prescription Drug Promotion (OPDP) sent an
untitled letter
to Exeltis over “false and misleading” claims in a social media post for its progestin-only birth control pill.
The sponsored
post
for Slynd (drospirenone) overstated the efficacy of the drug, OPDP claims, with wording that the pill could give patients “periods on a schedule.” OPDP disputed the claim in its letter, pointing to Exeltis’ clinical studies showing the majority of patients did not experience schedule-like periods over the course of treatment.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
-靶点
-药物
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。